IMDX raises $26M in registered direct offering; funds heart transplant rejection test development

The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.

On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.